{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:01:17Z","timestamp":1790204477175,"version":"4.1.0"},"reference-count":76,"publisher":"Georg Thieme Verlag KG","issue":"09","funder":[{"name":"Deutsche Forschungsgemeinschaft","award":["Germany\u2019s Excellence Strategy \u2013 EXC-3105\/1 \u2013"],"award-info":[{"award-number":["Germany\u2019s Excellence Strategy \u2013 EXC-3105\/1 \u2013"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) has undergone a major conceptual shift from a steatosis-centred condition to a disease spectrum, in which advanced fibrosis is the major prognostic determinant. It affects up to one-third of the adult population but remains asymptomatic in the majority of patients. Therefore, the efficient identification of at-risk individuals is a central clinical task. Non-invasive tests increasingly complement histological staging and are embedded in sequential diagnostic algorithms. In particular, FIB-4, as a first-line screening tool followed by vibration-controlled transient elastography for liver stiffness assessment, has been adopted by expert recommendations and clinical guidelines.<\/jats:p>\n                  <jats:p>These non-invasive tests have proven relevance to clinical endpoints beyond risk stratification and indications for MASLD-specific therapy. However, dynamic changes and their prognostic implications during treatment require further prospective evaluation. This review summarizes the current diagnostic strategies for MASLD and discusses their implementation in the German healthcare context.<\/jats:p>","DOI":"10.1055\/a-2906-2253","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:07:08Z","timestamp":1787180828000},"page":"1273-1280","source":"Crossref","is-referenced-by-count":0,"title":["The utility of emerging fibrosis scoring systems in MASLD: A paradigm shift toward non-invasive, multimodal risk stratification beyond histology"],"prefix":"10.1055","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8109-8526","authenticated-orcid":false,"given":"Thomas","family":"Karlas","sequence":"additional","affiliation":[{"name":"Leipzig University Medical Center, Germany","place":["Leipzig"],"department":["Division of Gastroenterology, Department of Medicine II"]},{"name":"Leipzig University, SN, Germany","place":["Leipzig"],"department":["LeiCeM - Leipzig Center of Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6420-3549","authenticated-orcid":false,"given":"Eva Katharina","family":"Messer","sequence":"additional","affiliation":[{"name":"Leipzig University, SN, Germany","place":["Leipzig"],"department":["LeiCeM - Leipzig Center of Metabolism"]},{"name":"Leipzig University Medical Center, Germany","place":["Leipzig"],"department":["Division of Hepatology, Department of Medicine II"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9233-4064","authenticated-orcid":false,"given":"Johannes","family":"Wiegand","sequence":"additional","affiliation":[{"name":"Leipzig University, SN, Germany","place":["Leipzig"],"department":["LeiCeM - Leipzig Center of Metabolism"]},{"name":"Leipzig University Medical Center, Germany","place":["Leipzig"],"department":["Division of Hepatology, Department of Medicine II"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2013.02.002","article-title":"Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae","author":"T Karlas","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","author":"ME Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101557","article-title":"Real-world evidence in metabolic dysfunction-associated steatotic liver disease (MASLD): insights, challenges, and future directions","author":"H-T Huang","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","author":"H Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70603","article-title":"Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-The-Art Review","author":"KMA van Eekhout","year":"2026","journal-title":"Liver Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-335542","article-title":"Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring","author":"G Feng","year":"2025","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","author":"FE M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70553","article-title":"Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines","author":"F Bril","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","author":"SA Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","author":"AJ Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","author":"MP Bonaca","year":"2025","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(25)00260-2","article-title":"Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis","author":"W Li","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00189-5","article-title":"Type 2 diabetes, prediabetes, and MASLD: who and when to screen and how to treat?","author":"CD Byrne","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1055\/a-2769-2397","article-title":"Amendment \u201eResmetirom\u201c zur S2k-Leitlinie \u201eMetabolische Lebererkrankungen\u201c (vormals \u201eNicht-alkoholische Fettlebererkrankung\u201c v.2.0\/April 2022) der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 2.3)","author":"E Roeb","year":"2026","journal-title":"Z Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/a-1880-2388","article-title":"Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS): April 2022 \u2013 AWMF registration No. 021\u2013025","author":"F Tacke","year":"2022","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70281","article-title":"Limitations of Guideline-Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments","author":"M Franck","year":"2025","journal-title":"Liver Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/a-2592-6109","article-title":"Einsch\u00e4tzung der Anwendbarkeit von Resmetirom bei Patienten mit MASH: Ergebnisse aus dem Deutschen Register f\u00fcr Steatotische Lebererkrankungen","author":"EK Messer","year":"2025","journal-title":"Z Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease","author":"P Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","author":"H Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.03.042","article-title":"Noninvasive Assessment of Liver Fibrosis in NAFLD","author":"AJ Sanyal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100222","article-title":"Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding","author":"WH Chang","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32163","article-title":"Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases","author":"P Gin\u00e8s","year":"2022","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease","author":"L Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis","author":"S McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","author":"P Angulo","year":"2007","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis","author":"Y Vali","year":"2020","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","author":"FE M\u00f3zes","year":"2022","journal-title":"Gut"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020192437","article-title":"Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement","author":"RG Barr","year":"2020","journal-title":"Radiology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2024.03.013","article-title":"WFUMB Guideline\/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography","author":"G Ferraioli","year":"2024","journal-title":"Ultrasound Med Biol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography","author":"J-X Liang","year":"2023","journal-title":"J Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0392","article-title":"Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","author":"YE Chon","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.5009\/gnl19173","article-title":"Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease","author":"E Kaya","year":"2020","journal-title":"Gut Liver"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","author":"ME Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary","year":"2024","journal-title":"Diabetologia"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001658","article-title":"Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease","author":"Y Zhang","year":"2025","journal-title":"Hepatology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001946","article-title":"Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals","author":"F Eren","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","year":"2021","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH\/NASH and Moderate to Noncirrhotic Advanced Fibrosis","author":"M Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.09.205","article-title":"Reliable Monitoring of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Using Imaging: A Systematic Literature Review and Meta-Analysis on Measurement Repeatability","author":"M Ndaa","year":"2026","journal-title":"Endocr Pract"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14176148","article-title":"Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD","author":"K Iwaszko-Sochal","year":"2025","journal-title":"J Clin Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","author":"PN Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102310","article-title":"FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial","author":"V Wai-Sun Wong","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.10.034","article-title":"Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores","author":"AJ Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","author":"SA Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.031","article-title":"NIS2+, an optimisation of the blood-based biomarker NIS4 technology for the detection of at-risk NASH: A prospective derivation and validation study","author":"SA Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.03.044","article-title":"Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis","author":"F Tavaglione","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14621","article-title":"Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH","author":"J Boursier","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.03.032","article-title":"Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients","author":"CM Canivet","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13813","article-title":"Performance of novel collagen turnover biomarkers to detect increased liver stiffness in MASLD","author":"H Hegmar","year":"2024","journal-title":"J Intern Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30163","article-title":"ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis","author":"SJ Daniels","year":"2019","journal-title":"Hepatology"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","author":"M Noureddin","year":"2022","journal-title":"J Hepatol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.02.003","article-title":"MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death","author":"E Truong","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322976","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","author":"J Jung","year":"2021","journal-title":"Gut"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.01.023","article-title":"Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD","author":"N Tamaki","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","author":"VL Chen","year":"2025","journal-title":"Hepatology"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.02.014","article-title":"Non-invasive Identification of Metabolic Dysfunction-associated Steatotic Liver Disease Patients Eligible for Resmetirom Treatment","author":"K John","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.02.035","article-title":"Novel Noninvasive Tests for Liver Fibrosis: Moving Beyond Simple Tests in Metabolic Dysfunction-associated Steatotic Liver Disease","author":"JT Grady","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2020.1766554","article-title":"Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)","author":"F Gerhardt","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.008","article-title":"Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease","author":"H Hagstr\u00f6m","year":"2020","journal-title":"Gastroenterology"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100780","article-title":"Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study","author":"QM Anstee","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-337506","article-title":"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes","author":"Y Chen","year":"2026","journal-title":"Gut"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.03.029","article-title":"Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society","author":"D Petroff","year":"2018","journal-title":"Dig Liver Dis"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15941","article-title":"Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: A qualitative exploration of challenges and barriers","author":"EA Tsochatzis","year":"2024","journal-title":"Liver Int"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07706-2","article-title":"Primary Care Providers and Nonalcoholic Fatty Liver Disease: A Needs Assessment Survey","author":"KB Islam","year":"2023","journal-title":"Dig Dis Sci"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj-2025-0026","article-title":"Barriers and facilitators to liver fibrosis screening: Perspectives and practices of Canadian primary care physicians","author":"DA Dinh","year":"2025","journal-title":"Can Liver J"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06087-7","article-title":"Surveillance of the liver in type 2 diabetes: important but unfeasible?","author":"S Qadri","year":"2024","journal-title":"Diabetologia"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","author":"A Srivastava","year":"2019","journal-title":"J Hepatol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0094","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association","author":"K Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.02.018","article-title":"Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes","author":"T Vidal-Tr\u00e9can","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(26)01692-2","article-title":"WED-154-YI FIB-4 screening in primary care identifies one in five patients with diabetes mellitus at risk of fibrotic MASLD for specialist referral","author":"EK Messer","year":"2026","journal-title":"J Hepatol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101122","article-title":"Successful hepatitis B and C screening in the health check-up in the German primary care setting","author":"O B\u00e4tz","year":"2024","journal-title":"JHEP Rep"},{"issue":"02","key":"ref72","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s15036-026-4005-3","article-title":"Screening auf Hepatitis B und C \u2013 eine Zwischenbilanz","volume":"13","author":"D H\u00fcppe","year":"2026","journal-title":"Gastro-News"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(26)00011-7","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease, 1990\u20132023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023","author":"GBD 2023 MASLD Collaborators","year":"2026","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"ref75","first-page":"5","article-title":"Umsetzung der Laborreform 2025: F\u00fcr die fach\u00e4rztlichen Labore kommt es so schlecht wie erwartet","volume":"3","author":"M M\u00fcller","year":"2025","journal-title":"LM Aktuell SPEZIAL"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00270-4","article-title":"Implementation of a liver health check in people with type 2 diabetes","author":"KWM Abeysekera","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2026.2615408","article-title":"Metabolic biomarkers add little to diagnostic performance of FIB-4 in MASLD","author":"S Ullman","year":"2026","journal-title":"Scand J Gastroenterol"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2906-2253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:31:18Z","timestamp":1790202678000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2906-2253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":76,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2906-2253","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}